Algorae Signs License and Supply Agreement with Cadila
Filed with ASX · · 3 pages · English
• Algorae finalises Licence & Supply Agreement (“LSA”) with Cadila Pharmaceuticals to launch two generic medicines targeting cardiovascular and metabolic disorders in Australia and New Zealand (“ANZ”). • Cadila to develop and manufacture product; Algorae to act as TGA sponsor and commercialise under its AlgoraeRx commercial division. • Agreement complements existing oncology-focused licensing agre
Algorae Pharmaceuticals Limited on 6ix
Story so far
Earlier from Algorae Pharmaceuticals
- Quarterly Activities Report /Appendix 4C Cash Flow Statement
- $3 million Debt Facility Secured with ScotPac
- AlgoraeOS v2 Identifies 90 Drug Combination Candidates
- Algorae Receives $384,466.78 R&D Tax Incentive Refund
- Peter Mac Testing Validates AlgoraeOS - v2 Launched
Later from Algorae Pharmaceuticals
- Half Year Report and Appendix 4D
- Peter Mac Partners with Algorae on AI Validation
- TGA Accepts Initial Registration Dossier for Evaluation
- Algorae Pharmaceuticals Ltd Raises $3.9m
- Algorae and Zydus Enter Exclusive Commercial Agreement
Follow Algorae Pharmaceuticals into a list and get an email when it puts out news.
Follow Algorae Pharmaceuticals